Immunotec Inc.

TSX VENTURE : IMM


Immunotec Inc.

December 29, 2011 16:00 ET

Immunotec Mourns the Death of Dr. Gustavo Bounous

VAUDREUIL-DORION, QUEBEC--(Marketwire - Dec. 29, 2011) - (TSX VENTURE:IMM)

Editors Note: A photo for this release will be available on the Canadian Press picture wire via Marketwire.

It is with profound sadness that Immunotec Inc. Executive Chairman and CEO Robert M. Henry announces the passing of Dr. Gustavo Bounous at the age of eighty-three.

Born in Luserna, Italy in 1928 and educated at the University of Turin and the University of Genoa, Dr. Gustavo Bounous' distinguished career in medical research began as a Research Fellow in surgery at the Indiana Medical Center, Indianapolis led to his appointment as Professor of Surgery, first at the University of Sherbrooke (1973-1985) and then at McGill University (1985-1993). Dr. Bounous was awarded the 1965 medal of the Royal College of Physicians and Surgeons of Canada. In 1968, he was named Career Investigator of the Medical Research Council, an award that was reconfirmed until 1993, the year of his retirement from McGill University.

In 1978, Dr. Bounous initiated a novel research program in conjunction with colleagues from the McGill University Faculty of Medicine to search for a dietary protein source that would boost the immune system. Their research led to the isolation and preparation of an undenatured milk concentrate that helps to sustain normal glutathione levels and a strong immune system. Subsequent identification of the active ingredients present in this protein mixture led to the development of a high-quality bioactive material given the name Immunocal® which was trademarked in 1993. Dr. Bounous later commented: "Discoveries are not made by scientific committee; they're made by individuals who have been lucky and persistent."

"Dr. Bounous leaves behind an incredible legacy," notes Robert Henry. "His research led to the development of a product that has impacted many thousands of lives. During this time of great loss, it is comforting to realize that his genius did not merely exist in a research laboratory, but lives on in the improved health of the many, many people who have benefited from Immunocal."

Immunotec Co-founder, Dieter Beer, funded Dr. Bounous' work after his retirement and invested in the early patents for Immunocal. He remembers Dr. Bounous as a very likeable man of vision, who was the embodiment of enthusiasm and humor. "One of the major events of my life was the opportunity to meet and work with him," he said. "He has had a profound impact on me for which I am very grateful."

Immunotec Vice-President, Research & Development, John Molson worked at the right-hand of Dr. Bounous for over ten years. "Most of us spend our lives witnessing genius from afar, whether it is a young prodigy in a concert hall or a professional athlete executing a move in a sporting match that defies the laws of physics. To have had the opportunity to work with one whose brilliance extended far beyond that of his scientific endeavors was to say the least, a life-changing experience. I feel deeply privileged to have met and worked with a true genius whose work will make a difference in the lives of millions for generations to come."

Son of the late Ada and Carlo Bounous, Dr. Bounous is survived by his beloved sister Luciana Bounous living in Italy. He will be missed by many friends and colleagues that enjoyed his great wit and charm, and equally by the thousands of individuals that have been helped by his extraordinary contributions to medical research.

Contributions in memory of Dr. Bounous may be made in his name to the charity of your choice.

About Immunotec Inc.

Immunotec is a network marketing company, offering a world-class business opportunity, supported by unique, scientifically-proven health products. Its cornerstone product, Immunocal®, is clinically proven to optimize the immune system. Headquartered near Montreal, Canada, the Company operates seamlessly in Canada, the United States, Mexico, the United Kingdom, Ireland and the Caribbean.

The Company files its press releases and such other required documents on the SEDAR database at www.sedar.com and on the Company's website at www.immunotec.com. The common shares of the Company are listed on the TSX Venture Exchange under the ticker symbol IMM.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Immunotec's most recent Management's Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.

To view the photo associated with this press release, please visit the following link: http://www.marketwire.com/library/20111229-Bounous_Immunotec_800.jpg

"The TSX Venture does not accept responsibility for the adequacy or accuracy of this release."

Contact Information

  • Daniel Audet
    Vice-President, Marketing
    (450) 510-4462